StageZero Life Sciences (GNWSF) Stock Price, News & Analysis

Company Overview

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.00 to $0.03
• 52-Week Range: $0.00 to $1.27
• Volume: N/A
• Average Volume: 26,719 shs
• Market Capitalization: $1.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNWSF Stock Analysis - Frequently Asked Questions

How have GNWSF shares performed this year?

StageZero Life Sciences' stock was trading at $0.0016 at the beginning of 2025. Since then, GNWSF stock has increased by 1,692.9% and is now trading at $0.0287.
View the best growth stocks for 2025 here.

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostic Substances
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNWSF
• CIK: 1454263
• Web: www.stagezerolifesciences.com
• Phone: 905-209-2030
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.86 million
• Net Margins: -200.26%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -165.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $4.15 million
• Price / Sales: 0.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -1.43

Miscellaneous

• Outstanding Shares: 62,995,000
• Free Float: N/A
• Market Cap: $1.81 million
• Optionable: Not Optionable
• Beta: 0.28